Join
Live feed
·
PRReleasevia Quantisnow
Genmab A/S logo

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

ByQuantisnow·Wall Street's wire, on your screen.
GMAB· Genmab A/S
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GMAB (Genmab A/S) and more on Quantisnow.